MyoKardia Readies First-Ever Hypertrophic Cardiomyopathy Drug For US Filing
Executive Summary
The Phase III EXPLORER-HCM trial evaluating mavacamten in obstructive hypertrophic cardiomyopathy (oHCM) succeeded on all primary and secondary endpoints.
You may also be interested in...
Bristol’s Mavacamten Shows Consistent Efficacy, Safe Use In Obstructive HCM At ACC
Long-term results from the EXPLORER-HCM extension study are consistent with the pivotal trial in obstructive hypertrophic cardiomyopathy, while data from VALOR may support a supplemental filing.
REMS For Mavacamten Could Involve Additional Monitoring, BMS Says
The FDA will take three more months to review mavacamten, a treatment for hypertrophic cardiomyopathy that BMS expects to be one of the company’s next blockbusters.
BMS Buys MyoKardia, Plans To Use Eliquis Experience To Grow Mavacamten
Paying $13.1bn for MyoKardia and its potential first-in-class HCM drug, BMS sees a blockbuster sales opportunity that it will grow gradually. MyoKardia team will be absorbed into BMS, Caforio says.